Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsJSE:APN +2.70%74 EV-to-FCF is 32.17 as of Jul. 13, 2026, which is 19% below its 10-year median of 39.96. GuruFocus rates JSE:APN with a GF Score™ of 74/100 and a GF Value™ of R170.77 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 562 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 61.21% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aspen Pharmacare Holdings's Enterprise Value is R94,393 Mil.
Aspen Pharmacare Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was R2,934 Mil. Therefore, Aspen Pharmacare Holdings's EV-to-FCF for today is 32.17.
The historical rank and industry rank for Aspen Pharmacare Holdings's EV-to-FCF or its related term are showing as below:
JSE:APN'
s EV-to-FCF Range Over the Past 10 Years
Min: -148.48 Med: 39.96 Max: 959.11
Current: 32.17
During the past 13 years, the highest EV-to-FCF of Aspen Pharmacare Holdings was 959.11. The lowest was -148.48. And the median was 39.96.
JSE:APN's EV-to-FCF is ranked worse than 61.21% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs JSE:APN: 32.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspen Pharmacare Holdings's PE Ratio (TTM) for today is calculated as:
Aspen Pharmacare Holdings's share price for today is R151.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was R-4.505.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aspen Pharmacare Holdings EV-to-FCF Related Terms
Aspen Pharmacare Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's EV-to-FCF falls into.
Aspen Pharmacare Holdings's current Enterprise Value is R94,393 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was R2,934 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (JSE:APN) has a EV-to-FCF of 32.17 as of Jul. 13, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aspen Pharmacare Holdings and its competitors. This is 19% below median its historical median of 39.96. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #344 out of 562 companies in the Drug Manufacturers industry, placing it in the top 61.2%.
Is Aspen Pharmacare Holdings' EV-to-FCF too high?
Aspen Pharmacare Holdings' current EV-to-FCF of 32.17 is 19% below median its 10-year median of 39.96. The Drug Manufacturers industry median EV-to-FCF is 20.96. Aspen Pharmacare Holdings' value of 32.17 is 53.5% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #344 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #344 out of 562 companies for EV-to-FCF. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median EV-to-FCF is 20.96. Aspen Pharmacare Holdings' value of 32.17 is 53.5% above this benchmark. While the company's 10-year median is 39.96 vs. the industry median of 20.96, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current EV-to-FCF of 32.17 is 53.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current EV-to-FCF is 32.17, which is 19% below median its own 10-year median of 39.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R170.77, compared to a current price of R151.05 — trading 11.5% below its estimated fair value. The current EV-to-FCF is 32.17, which is 19% below median its 10-year median of 39.96 and 53.5% above the Drug Manufacturers industry median of 20.96. Aspen Pharmacare Holdings' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current EV-to-FCF is 32.17 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R151.05 is trading 11.5% below its estimated GF Value™ of R170.77.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
EV-to-FCF: 32.17 (19% below median its 10-year median of 39.96)
GF Value™: R170.77 vs. price of R151.05 (11.5% below fair value)
Industry Position: 53.5% above the Drug Manufacturers median (#344 of 562)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
74GF Score
Get the complete analysis for JSE:APN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
